At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 207 enrolled
Drug / intervention
Apremilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease
In Brief
A Phase 3 clinical trial evaluating Apremilast and Placebo for Behçet's Syndrome. Completed, enrolled 207 participants across 63 sites in 10 countries.
Detailed Summary
The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBehçet's Syndrome
CountriesFrance, Germany, Greece, Israel, Italy, Japan, Lebanon, South Korea, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartDec 2014
Primary CompletionSep 2017
Study CompletionJul 2020
TodayJul 2026
First PostedDec 4, 2014
Enrollment StartDec 30, 2014
Primary CompletionSep 25, 2017
Study CompletionJul 17, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.6 years ago
Interventions
Apremilastdrug
Tablets for oral administration
Placebodrug
Tablets for oral administration